Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Catioprost vs Travatan Z in Glaucoma/OHT with OSD
NCT01254370Phase 2Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Nov 2010
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Catiolanze in Glaucoma and ocular hypertension (2 arms), sponsored by Santen Pharmaceutical. Primary endpoints: Change from baseline in Intraocular Pressure at 3 months and Change in Ocular Surface Disease at 3 months. Started Nov 2010; status: completed.
02
Drugs
Catiolanze
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on NCT01254370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01254370.